353 related articles for article (PubMed ID: 12097563)
1. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins.
Haglund K; Leiner I; Kerksiek K; Buonocore L; Pamer E; Rose JK
J Virol; 2002 Aug; 76(15):7506-17. PubMed ID: 12097563
[TBL] [Abstract][Full Text] [Related]
2. High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses.
Haglund K; Leiner I; Kerksiek K; Buonocore L; Pamer E; Rose JK
J Virol; 2002 Mar; 76(6):2730-8. PubMed ID: 11861840
[TBL] [Abstract][Full Text] [Related]
3. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
4. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
5. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.
Publicover J; Ramsburg E; Rose JK
J Virol; 2005 Nov; 79(21):13231-8. PubMed ID: 16227246
[TBL] [Abstract][Full Text] [Related]
6. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.
Ramsburg E; Rose NF; Marx PA; Mefford M; Nixon DF; Moretto WJ; Montefiori D; Earl P; Moss B; Rose JK
J Virol; 2004 Apr; 78(8):3930-40. PubMed ID: 15047809
[TBL] [Abstract][Full Text] [Related]
7. Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice.
Andersson AC; Holst PJ
J Transl Med; 2016 Dec; 14(1):343. PubMed ID: 27998269
[TBL] [Abstract][Full Text] [Related]
8. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8
Li SS; Kochar NK; Elizaga M; Hay CM; Wilson GJ; Cohen KW; De Rosa SC; Xu R; Ota-Setlik A; Morris D; Finak G; Allen M; Tieu HV; Frank I; Sobieszczyk ME; Hannaman D; Gottardo R; Gilbert PB; Tomaras GD; Corey L; Clarke DK; Egan MA; Eldridge JH; McElrath MJ; Frahm N;
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28931520
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.
Rose NF; Roberts A; Buonocore L; Rose JK
J Virol; 2000 Dec; 74(23):10903-10. PubMed ID: 11069984
[TBL] [Abstract][Full Text] [Related]
11. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
[TBL] [Abstract][Full Text] [Related]
12. Requirement for CD4 T cell help in maintenance of memory CD8 T cell responses is epitope dependent.
Ramsburg EA; Publicover JM; Coppock D; Rose JK
J Immunol; 2007 May; 178(10):6350-8. PubMed ID: 17475864
[TBL] [Abstract][Full Text] [Related]
13. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.
Tan GS; McKenna PM; Koser ML; McLinden R; Kim JH; McGettigan JP; Schnell MJ
Virology; 2005 Jan; 331(1):82-93. PubMed ID: 15582655
[TBL] [Abstract][Full Text] [Related]
14. Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.
Hovav AH; Cayabyab MJ; Panas MW; Santra S; Greenland J; Geiben R; Haynes BF; Jacobs WR; Letvin NL
J Virol; 2007 Jan; 81(1):74-83. PubMed ID: 17050608
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.
De Rose R; Batten CJ; Smith MZ; Fernandez CS; Peut V; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Venturi V; Davenport MP; Kent SJ
J Virol; 2007 Jan; 81(1):292-300. PubMed ID: 17050602
[TBL] [Abstract][Full Text] [Related]
16. Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.
Schell JB; Rose NF; Bahl K; Diller K; Buonocore L; Hunter M; Marx PA; Gambhira R; Tang H; Montefiori DC; Johnson WE; Rose JK
J Virol; 2011 Jun; 85(12):5764-72. PubMed ID: 21490100
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of the vaccinia virus LC16m8Δ vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol.
Sato H; Jing C; Isshiki M; Matsuo K; Kidokoro M; Takamura S; Zhang X; Ohashi T; Shida H
Vaccine; 2013 Aug; 31(35):3549-57. PubMed ID: 23731631
[TBL] [Abstract][Full Text] [Related]
18. Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'.
Chen Z; Huang Y; Zhao X; Ba L; Zhang W; Ho DD
J Acquir Immune Defic Syndr; 2008 Apr; 47(4):412-21. PubMed ID: 18209682
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses.
Lawrence TM; Wanjalla CN; Gomme EA; Wirblich C; Gatt A; Carnero E; García-Sastre A; Lyles DS; McGettigan JP; Schnell MJ
PLoS One; 2013; 8(6):e67123. PubMed ID: 23840600
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide.
Gherardi MM; Ramírez JC; Esteban M
J Virol; 2000 Jul; 74(14):6278-86. PubMed ID: 10864637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
